Skip to content
Austin Top 50
Author:
Invivyd, Inc.
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
September 29, 2026
Invivyd to Participate in Key Investor Conferences – Sept 2026
September 8, 2026